GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HLB Life Science Co 067630.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,585

+1.17%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩45.75bn

FY2016FY2025

Net income

−₩99.79bn

FY2016FY2025

Free cash flow

−₩48.88bn

FY2016FY2025

Shareholders' equity

₩297.35bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩45.75bn₩102.24bn₩97.99bn₩99.59bn₩53.49bn₩91.80bn₩114.02bn₩102.48bn₩106.45bn₩42.23bn
Gross profit−₩494.4m−₩2.19bn−₩748.6m−₩3.05bn−₩3.05bn₩4.58bn₩7.61bn₩4.67bn₩5.41bn₩3.30bn
Research and development₩4.70bn₩5.18bn₩5.45bn₩4.35bn₩3.85bn₩1.43bn—₩1.32bn₩243.1m₩80.9m
Operating income−₩21.02bn₩18.13bn−₩65.51bn—−₩18.33bn−₩8.02bn−₩37.61bn−₩7.96bn₩1.79bn−₩1.41bn
Net income−₩99.79bn₩6.14bn−₩5.98bn−₩54.28bn−₩49.15bn−₩55.80bn−₩7.60bn−₩3.07bn₩7.76bn−₩1.25bn
Diluted earnings per share-819.0150.39-55.98-533.62-489.39-592.70-80.80-84.47136.25-24.75

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩478.09bn₩539.02bn₩423.50bn₩411.79bn₩270.80bn₩327.20bn₩404.94bn₩386.26bn₩99.02bn₩82.68bn
Cash and short-term investments———₩128.27bn₩139.96bn₩158.03bn₩175.76bn₩194.79bn₩30.26bn₩13.38bn
Total liabilities₩180.35bn₩140.19bn₩192.29bn₩177.07bn₩24.61bn₩40.02bn₩71.11bn₩167.17bn₩46.19bn₩54.99bn
Debt₩54.47bn₩82.53bn₩51.41bn₩147.47bn₩4.62bn₩11.39bn₩11.97bn₩93.70bn₩11.40bn₩23.16bn
Shareholders' equity₩297.35bn₩398.34bn₩230.80bn₩234.72bn₩246.19bn₩287.18bn₩333.82bn₩219.09bn₩52.83bn₩27.68bn
Shares outstanding122m122m107m102m100m94m94m36m57m51m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩22.93bn−₩32.01bn−₩10.02bn−₩29.74bn−₩14.08bn₩2.01bn−₩12.39bn−₩11.07bn−₩302.0m−₩2.27bn
Capital spending−₩25.94bn−₩27.47bn−₩21.52bn−₩11.65bn−₩2.42bn−₩8.41bn−₩9.08bn−₩386.0m−₩286.1m−₩1.30bn
Free cash flow−₩48.88bn−₩59.47bn−₩31.54bn−₩41.40bn−₩16.50bn−₩6.40bn−₩21.46bn−₩11.46bn−₩588.2m−₩3.57bn

Financial ratios

Data as of 1 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin-1.1%-2.1%-0.8%-3.1%-5.7%5.0%——
Operating margin-45.9%17.7%-66.9%—-34.3%-8.7%-4.7%—
Net margin-218.1%6.0%-6.1%-54.5%-91.9%-60.8%——
Return on equity-33.6%1.5%-2.6%-23.1%-20.0%-19.4%——
Return on assets-20.9%1.1%-1.4%-13.2%-18.2%-17.1%——
Free cash flow yield———————-10.7%
Revenue growth-55.3%4.3%-1.6%86.2%-41.7%-19.5%——
Earnings growth-1725.9%-202.6%-89.0%10.4%-11.9%633.7%——
Current ratio0.58x2.90x1.09x6.00x11.59x10.15x——
Debt to equity0.18x0.21x0.22x0.61x0.01x0.04x——
Equity ratio62.2%73.9%54.5%57.0%90.9%87.8%——
Interest coverage-1.79x1.08x-3.03x—-14.59x-3.80x——
R&D as a share of sales10.3%5.1%5.6%4.4%7.2%1.6%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-22.8%-13.0%5.3%
Operating income—21.3%4.0%
Net income22.5%12.3%19.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-1.8%-1.9%-1.0%1.3%
Operating margin-2.0%———
Net margin-63.3%-44.5%-52.7%-31.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-4.7198.7-204.5-19.9-24.2-21.8-163.3-96.826.8-100.9
Price to sales10.311.912.510.822.213.310.92.91.93.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1205-for-1174 split · 9 May 2024
  • 712-for-677 split · 28 Dec 2022
  • 2-for-1 split · 15 Mar 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.